| PEA0077 | In silico prediction of Human Leukocytes Antigen (HLA) class II binding Hepatitis B Virus (HBV) peptides in Botswana | E-Poster BU Poster exhibition | A30 |
| PEA0088 | Predictors of sensory neuropathy and neuropathic symptom worsening after 12 years in aging people with HIV | E-Poster BU Poster exhibition | A31 |
| PEA0078 | A challenge for HIV treatment: The long time to immune recovery of people living with HIV under antiretroviral therapy. A longitudinal study in a big state of Brazil | E-poster | A32 |
| PEA0079 | Diagnostic accuracy of Pan Degenerative Amplification and Adaption assay for drug resistance mutations among HIV-1 infected adolescents failing ART therapy in Zimbabwe: Role of a point mutation assay | E-poster | A33 |
| PEA0080 | A98S mutation/polymorphism on RT region of HIV-1 subtype C isolates: Possible impact of geographical variation on drug resistance | E-poster | A33 |
| PEA0081 | Improving geno2pheno[coreceptor] to predict the tropism of clinical HIV-1 CRF01_AE samples | E-poster | A33 |
| PEA0082 | Integrated Point-Of-Care (POC) diagnostics for TB and HIV (EID/VL) In Cameroon ' Early implementation results across five GeneXpert (GX) testing sites | E-poster | A33 |
| PEA0083 | Dose adjustment of doravirine mitigates the pharmacokinetic interaction with the moderate CYP3A inducer, rifabutin | E-poster | A34 |
| PEA0084 | Effects of INSTI and other ARV combinations on folate distribution via folate transporters: Implications for neural tube defects | E-poster | A34 |
| PEA0085 | Targeting tipranavir to mesenteric lymph nodes (MLNs) for improved treatment of HIV/AIDS | E-poster | A34 |